On June 12, 2025, TG Therapeutics, Inc. held its annual meeting where over 74% of shareholders voted to approve the election of directors and other proposals, including increasing authorized shares in their 2022 Incentive Plan from 17 million to 22 million. All proposals were approved with varying support among directors, highlighting shareholder engagement and approval of executive compensation.